Probiotics are one of the most heavily marketed supplement categories in UK pharmacy, and one of the most variable in what they actually claim to do. Some uses — antibiotic-associated diarrhoea, specific forms of IBS, infant colic — have a reasonable evidence base in randomised trials. Others — general "gut health", skin conditions, mental wellbeing, immunity, weight management — are claimed on packaging without matching clinical evidence.
This article summarises where UK guidance and systematic reviews currently place probiotics, what to look for on a label, and where the counter conversation should stop promising and start referring.
What a probiotic actually is
The WHO/FAO definition, widely used, is "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". Two practical consequences follow:
- Strain specificity matters. Evidence for Lactobacillus rhamnosus GG in one context does not transfer to a different strain in the same genus. Products sold under the same broad heading can have completely different evidence bases depending on strain and dose.
- Dose is measured in colony-forming units (CFU). Trials often use 10⁹ to 10¹⁰ CFU per day; lower-dose products may not reproduce the effects seen in trials.
A well-specified product lists its strains (genus, species, strain designation) and its CFU count at end of shelf life, not at manufacture.
Where the evidence is strongest
Antibiotic-associated diarrhoea
This is the probiotic use with the strongest evidence base. Cochrane reviews and meta-analyses suggest that co-administration of certain probiotic strains during antibiotic courses reduces the risk of antibiotic-associated diarrhoea, particularly Clostridioides difficile infection, in both adults and children. The effect sizes are modest but consistent.
The strains with the best data are Saccharomyces boulardii and selected Lactobacillus strains (e.g. L. rhamnosus GG). NICE does not yet recommend probiotics for routine prevention of antibiotic-associated diarrhoea, but the pharmacy counter-conversation — "starting antibiotics, want to protect my gut" — is reasonable to discuss if the evidence caveats are clear.
Irritable bowel syndrome
NICE CKS on IBS notes that some patients may find probiotics helpful for symptom management, and advises trying a product at the manufacturer's recommended dose for at least four weeks before judging efficacy. The evidence base is heterogeneous — different strains, different IBS subtypes — and the effect sizes are modest. The British Society of Gastroenterology IBS guideline takes a similar position.
Pharmacy advice usually pairs a probiotic trial with the rest of the IBS self-management package: the low-FODMAP dietary framework (often with dietitian input), stress management, fibre adjustment, and antispasmodic or laxative use as indicated.
Infant colic
Selected probiotic strains — particularly Lactobacillus reuteri DSM 17938 — have been studied in breastfed infants with colic, with some trials suggesting reduced crying time. NICE CKS and the BDA consider this evidence promising but not conclusive, and recommend it as an option to discuss rather than a universal treatment.
Traveller's diarrhoea
Some evidence supports probiotics for reducing the incidence or severity of traveller's diarrhoea, with inconsistent results across strains and trial settings. Standard advice — food and water hygiene, oral rehydration — remains the mainstay.
Where the evidence is weak or absent
Claims that appear on packaging but have limited high-quality trial support in the general population include:
- General "gut health" or "detoxification"
- Immunity boosting
- Mood, anxiety or stress
- Skin conditions such as acne or eczema in routine use
- Weight management
- Vaginal health in women not meeting specific clinical criteria
Absence of strong trial evidence is not the same as absence of benefit, but it does mean that counter claims should be cautious. A patient paying £20+/month for a general-wellness probiotic should hear clearly that the evidence for that particular use is limited.
Probiotics versus prebiotics versus synbiotics
- Probiotics: the live microbes themselves.
- Prebiotics: dietary fibres (inulin, oligofructose, resistant starch) that feed gut microbes.
- Synbiotics: combination products containing both.
The evidence for prebiotics as supplements is narrower than for well-designed dietary fibre intake (vegetables, fruit, legumes, wholegrains). Counter advice for general gut health should lean toward diet first, supplement second.
Safety
For healthy adults, probiotics are generally well tolerated. Specific contraindications and cautions include:
- Severe immunosuppression: rare reports of probiotic-associated bacteraemia or fungaemia in critically ill or severely immunocompromised patients. Discuss with the specialist team.
- Acute pancreatitis: a high-profile trial raised concerns about probiotic use in severe acute pancreatitis — this is a specialist context, not a pharmacy counter recommendation.
- Central venous catheters: some clinicians avoid live probiotics in patients with central lines because of rare translocation events.
- Products sold as supplements are not licensed medicines. Quality control is driven by the manufacturer; reputable brands provide batch-level CFU testing.
Reading the label
Useful checks at the counter:
| Label feature | What to look for |
|---|---|
| Strain specification | Genus, species, strain designation (e.g. L. rhamnosus GG) |
| CFU count | At end of shelf life, not at manufacture |
| Dose | Typically 10⁹–10¹⁰ CFU/day in trials |
| Storage | Refrigerated or shelf-stable; follow label |
| Regulatory status | UK food supplement regulations apply |
| Claims | UK/EU approved health claims are narrow; be sceptical of broad-wellness language |
When to refer
Persistent gastrointestinal symptoms merit clinical assessment, not indefinite supplement use. Red flags — weight loss, blood in stool, nocturnal symptoms, unexplained anaemia, change in bowel habit in an adult over 50 — are outside the pharmacy self-care remit.
Caveats
This article summarises NICE CKS, Cochrane, BSG and BDA guidance current to April 2026. Individual product decisions depend on strain, dose, patient context and clinician judgement.
Sources
- NICE Clinical Knowledge Summaries — Irritable bowel syndrome
- Cochrane — Probiotics for prevention of antibiotic-associated diarrhoea
- British Society of Gastroenterology — IBS guideline
- British Dietetic Association — Probiotics food fact sheet
Find an NHS community pharmacy for counter advice via PharmSee's pharmacy finder.